Lymphoedema Clinical Trial
Official title:
A Phase 2a Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, Pharmacokinetics, and Efficacy of Deupirfenidone (LYT-100) in Patients With Breast Cancer-Related Upper Limb Secondary Lymphoedema
Verified date | April 2022 |
Source | PureTech |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a trial of up to 6-months duration for safety, tolerability, clinical efficacy assessments, PK and biomarkers analysis in breast carcinoma patients with secondary lymphoedema
Status | Terminated |
Enrollment | 50 |
Est. completion date | September 9, 2022 |
Est. primary completion date | September 9, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Main Inclusion Criteria: 1. Female or male between 18 and 80 years old (inclusive) at the time of informed consent. 2. At least 6 months since any type of breast cancer surgery (excluding fine needle aspiration biopsy [FNA]), at the time of study screening. No intention to have breast reconstructive surgery, nipple reconstruction and/or tattooing during the course of the study. 3. At least 3 months since completion of all types of treatment for breast cancer, including but not limited to neoadjuvant, radiotherapy, chemotherapy and immunotherapy, at the time of study screening. 4. At least 3 months treatment of stable adjuvant treatment with hormonal or anti-HER2 therapy at the time of screening, with no planned changes to this therapy throughout the duration of the study. 5. Diagnosis of primary breast cancer, and without evidence of recurrence of breast cancer and/or metastasis for at least 6 months since breast cancer surgery, as determined at screening and baseline. 6. Documented evidence of Stage 1 or 2 lymphedema. 7. Receiving standard of care compression or agreeable to using care compression, or no compression at all = 4 weeks prior to screening and throughout the study. Main Exclusion Criteria: 1. Bilateral lymphoedema or history of bilateral axillary lymph node removal (i.e., sentinel lymph node or axillary lymph node dissection), or primary lymphoedema or lymphatic or vascular malformation, determined at screening. 2. Chronic administration (defined as more than 14 consecutive days) of immunosuppressants or other immune-modifying drugs within 3 months prior to study drug administration; corticosteroids are permitted at the discretion of the PI. 3. Recent history (in the 8 weeks prior to screening) of cellulitis, lymphangitis, dermatitis, necrotizing fasciitis, or current open wounds or sores in the affected extremity. 4. Stage III lymphoedema, or history of clinically diagnosed secondary lymphoedema greater than 4 years, determined at screening. 5. Initiated use of compression or manual lymphatic drainage or other lymphoedema therapies at the start of the study within 4 weeks of the screening visit. Rescreening is allowed following a course of stable compression regimen of > 4 weeks. |
Country | Name | City | State |
---|---|---|---|
Australia | Flinders University | Adelaide | |
Australia | Ballarat Health Services | Ballarat | Victoria |
Australia | University of the Sunshine Coast | Sippy Downs | Queensland |
Australia | Macquarie University Health Sciences Centre | Sydney | |
United States | Accel Research Network | Atlanta | Georgia |
United States | City of Hope National Medical Center | Duarte | California |
United States | MACRO Trials | Los Angeles | California |
United States | Accel Research Network | Maitland | Florida |
Lead Sponsor | Collaborator |
---|---|
PureTech | Novotech (Australia) Pty Limited |
United States, Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Safety and Tolerability: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Evaluate the safety and tolerability of LYT-100 as measured by TEAEs | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01864044 -
Prospective Observational Lymphoedema Intensive Treatment
|
||
Completed |
NCT01152099 -
A Clinical Trial About the Contribution of Manual Lymph Drainage in Complex Physical Therapy for Patients With Lymphoedema Secondary to Mastectomy
|
N/A | |
Completed |
NCT00215280 -
Epidemiology and Control of Mansonella Perstans Infection in Uganda
|
N/A | |
Completed |
NCT05169086 -
Comparison of Two Types of Bandages in the Treatment of Lymphoedema
|
||
Completed |
NCT03825263 -
Intermittent Pneumatic Compression for Treating Lower Limb Lymphoedema
|
N/A | |
Recruiting |
NCT03580109 -
Spa Therapy for Upper or Lower Limb Lymphoedema
|
N/A | |
Completed |
NCT02015897 -
Effect of Physical Therapy on Breast Cancer Related Lymphedema
|
N/A | |
Completed |
NCT02476357 -
A Study for Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Radical Lymph Node Dissection
|
N/A |